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ABSTRACT
Multiple-drug resistance in human cancer is a major problem. To circumvent 
this issue, clinicians combine several drugs. However, this strategy could backfire 
resulting in more toxic or ineffective treatments. Carbon nanotubes (CNTs), and 
particularly multi-walled nanotubes (MWCNTs), display intrinsic properties against 
cancer interfering with microtubule dynamics and triggering anti-proliferative, anti-
migratory and cytotoxic effects in vitro that result in tumor growth inhibition in 
vivo. Remarkably, these effects are maintained in tumors resistant to traditional 
microtubule-binding chemotherapies such as Taxol®. 
In the view of these properties, we investigate the use of MWCNTs in the 
development of active-by-design nanocarriers, attempting to enhance the effect of 
broadly-used chemotherapies. We compare the cytotoxic and the anti-tumoral effect 
of 5-Fluorouracil (5-FU) -an antimetabolite treatment of various forms of cancer- with 
that of the drug physisorbed onto MWCNTs. Our results demonstrate how the total 
effect of the drug 5-FU is remarkably improved (50% more effective) when delivered 
intratumorally coupled to MWCNTs both in vitro and in vivo in solid tumoral models. 
Our results demonstrate how using MWCNTs as anti-cancer drug delivery platforms 
is a promising approach to boost the efficacy of traditional chemotherapies, while 
considerably reducing the chances of resistance in cancer cells.
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INTRODUCTION
Most of the localized tumors are satisfactorily 
treated with surgery. Unfortunately, most aggressive 
cancers metastasize to distant organs and develop 
resistance to chemotherapy. For this reason, clinicians 
often need to combine different drugs to simultaneously 
interrupt cell proliferation pathways at various points, 
boosting the potential cytotoxic effect of the treatment. 
Regrettably, anti-cancer drug combination does not always 
work. For instances, Taxol® (paclitaxel) and 5-Fluorouracil 
(5-FU) inhibit different and complementary mechanisms 
in cancer cell proliferation but, they have been reported to 
interfere with each other, questioning the clinical use of 
this drug combination parenterally [1]. As an alternative, 
drug co-encapsulation has also been suggested as a 
possible way to increase the therapeutic response of the 
Taxol® + 5-FU mixture [2]. Here, we propose a new 
alternative to boost the chemotherapeutic effect of 5-FU 
with nanomaterials which intrinsically display antitumoral 
properties, interfering with cell proliferative mechanisms 
thus, complementing the cytotoxic effect of the drug. 
Carbon nanotubes (CNTs) have shown excellent 
properties and applications in nanobiotechnology [3–5]. 
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In particular, multi-walled CNTs (MWCNTs) can 
penetrate most biological barriers and infiltrate inside 
cells where they display unique biomimetic properties 
with the intracellular cytoskeletal polymers, mostly 
with microtubules [6]. These tubulin polymers, that are 
traditional targets for many anticancer therapies [7], share 
many properties with MWCNTs. Both self-assemble, 
have similar dimensions, are exceptionally resilient, and 
show comparable physical properties (for example, shear 
stress, bending stiffness and Young´s modulus) [6]. Their 
similarities prompt interaction in vitro [8] and in vivo [9], 
and the assemblage mixed functional bio-synthetic tubulin 
polymers that display an enhanced stability compared to 
conventional microtubules [10]. The increased stability 
of these mixed polymers causes critical changes in the 
cellular biomechanics, triggering the reported anti-
proliferative [9, 11], anti-migratory [12–14]  and cytotoxic 
effects in vitro in cancer cells [15–17], and significant anti-
tumoral effects in vivo [18, 19]. In addition, some studies 
show how MWCNTs are effective in cells and tumors 
that have developed resistance to Taxol® [18]. Thus, the 
microtubule-stabilizing effect of Taxol® -that binds a 
structural pocket in the β-tubulin polypeptide- could be 
significantly boosted when combined with MWCNTs, 
for these nanomaterials utilize an alternative microtubule 
stabilization mechanism, complementary to that Taxol® 
[10]. Summarizing, these results support the potential 
use of MWCNTs as anti-tumoral agents exclusively 
based on their intrinsic properties, using novel cytotoxic 
mechanisms.   
But despite these numerous advantages, the stigma 
of the structural similarity of CNTs with asbestos fibers 
has slowed down progress of these nanomaterials in 
medicine, and have been repeatedly excluded in the 
design of drug nanocarriers [20]. Fortunately, the recent 
discovery of a series of surface treatments that make 
MWCNTs more biocompatible and bio-degradable by 
phagocytic cells, has opened many new opportunities in 
nanomedicine [21–27]. It is now known that macrophages 
in vitro can degrade surface-oxidized MWCNTs in 
few days, reducing the length of the nanotubes in 
approximately 30%, and in vivo, in the tumoral tissue 
after triggering significant antitumoral effects [19]. Here 
we investigate the possibility of enhancing the effect for 
traditional cancer drugs using MWCNTs as nanocarrier 
adjuvant systems. For the study we have loaded MWCNTs 
with 5-FU, a routine broadly used anticancer drug that 
inhibits cell replication mostly in the “S” phase of the cell 
cycle, complementing the intrinsic microtubule dynamics 
inhibitory effect of MWCNTs during mitosis (Figure 1). 
RESULTS AND DISCUSSION
Characterization of the 5-FU physisorption on 
MWCNTs and in vitro drug release
Simple molecular physisorption via π-stacking has 
been broadly used for successful loading of different drugs 
onto graphene and MWCNTs preventing drug inactivation 
due to the binding procedure (Figure 2A) [28, 29]. In this 
study, we have physisorbed 5-FU on MWCNTs (5-FU-
MWCNTs) as described in the methods section. The 
amount of the physisorbed 5-FU was estimated using 
thermogravimetric analysis (TGA). Figure 2B shows the 
TGA analysis where approximately 3% of the total mass 
of the 5-FU-MWCNT sample corresponds to the drug. 
This data was further corroborated using fluorescence 
spectroscopy analysis as a complementary technique 
(Supplementary Figures 1–2). This analysis served to 
verify the calculated amount of ca. 3 mg of 5-FU per 
100 mg of MWCNTs (3% w/w). Hence, this data will be 
considered in the comparative studies that follow.
5-FU release from the 5-FU-MWCNTs was first 
evaluated in vitro. For this purpose, 5-FU-MWCNTs were 
Figure 1: Cell cycle MWCNTs and 5-FU blockage points. (left) MWCNTs typically interfere with the mitosis process. (center) 
5-FU blocks the cell cycle at the “S” phase, during DNA and organelle replication. (right) Sequential and complementary blockage points 
of MWCNTs and 5-FU therapies. The expected double blockage of the cell cycle should inhibit cancel cell growth more intensively.
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exposed to physiological conditions (phosphate buffer pH 
= 7.4 at 37° C) during 140 h. Measurement of the collected 
samples using fluorescence spectroscopy suggested an 
initial phase of ‘burst’ release of the drug during the first 
24 h, that corresponded to a 40–42% of the loaded 5-FU. 
This was followed by a ‘sustained release’ phase where 
the rest of the drug was slowly discharged in the course of 
several days (Supplementary Figure 3). 
Boosted anti-proliferative and cytotoxic effects to 
5-FU when administered on MWCNTs 
To evaluate the effect of the 5-FU loaded MWCNTs 
in vitro, we exposed HeLa cell cultures to: 3 μg/mL 
of the plain drug; 100 μg/mL of pristine MWCNTs 
(p-MWCNTs); and finally, to 100 μg/mL of 5-FU-
MWCNTs. The effects of the treatments were compared 
72 h after exposure to the three therapies. 
Both, the resuspended 5-FU and 5-FU-MWCNTs 
produced a potent anti-proliferative effect accompanied 
by an obvious increase in the cellular size compared to 
untreated controls, or to cells treated with p-MWCNTs. 
This phenotype suggested a possible blockage in the 
“S” part of the cell cycle (Figure 3). Remarkably, 
cultures treated with 5-FU-MWCNTs appeared more 
severely affected that those treated with the free drug or 
p-MWCNTs.
Quantification of the cellular area in cultures 
treated with both, 5-FU and 5-FU-MWCNT, revealed 
a statistically significant 3-fold increase in cell size 
compared to untreated or p-MWCNTs controls 
(Supplementary Figure 4). As previously reported for 
MWCNTs [9], cells treated with 5-FU loaded onto 
MWCNTs also displayed characteristic long and thin 
cytoplasmic extensions resulting of the biomimetic 
interaction between MWCNTs with the cytoskeletal 
Figure 2: Characterization of the 5-FU-MWCNTs. (A) Representative diagram of the interaction between CNTs and 5-FU. 
(B) TGA corresponding to p-MWCNTs and 5-FU-MWCNTs samples under air atmosphere. An approximate 3% mass loss corresponding 
to the physisorbed 5-FU is calculated. 
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microtubules (Figure 3, solid arrows, Supplementary 
Figure 4). In addition, these cultures also presented the 
expected low surviving cellular rate. The abundance 
of cells with patent signs of apoptosis (empty arrows) 
supported the efficiency of this cytotoxic treatment in vitro 
and suggested a significant rise in the efficacy of the drug 
when applied decorating MWCNTs. 
A double cell cycle blockage to intensify the 
therapeutic effect 
To perform an accurate qualitative and quantitative 
analysis of the cytotoxic effects of the treatment, we used 
flow cytometry. This statistically powerful technique 
allows the characterization of the cell cycle for each 
condition, and to quantify the percentage of apoptotic 
cells in approximately 10,000 cells per experiment. For 
the study we used human HeLa cells and murine B16F10 
cells. This murine model of malignant melanoma cells is 
resistant to many traditional chemotherapeutic drugs [30] 
and, as the majority of melanomas, displays an aggressive 
nature, being genetically heterogeneous and highly 
metastatic [31]. 
Figure 4 illustrates the proportion of live cells 
(blue) vs. dead cells (red) for untreated controls and for 
the 3 different treatments: p-MWCNTs, 5-FU, and 5-FU-
MWCNTs. These data reveal a significant blockage in 
the “S” phase, 72 h post-treatment typical of 5-FU for 
both, HeLa and melanoma cells. More interestingly, 
both cell lines showed higher sensitivity to the cytotoxic 
effect of the 5-FU-MWCNTs compared to the plain drug. 
Cytotoxicity in cells treated with standard 5-FU was 14% 
and 17% for HeLa and melanoma cells, respectively. 
Parallel cultures treated with the same amount of 5-FU 
physisorbed onto MWCNTs displayed 21% and 27% 
cell death, respectively (Figure 4, red). Furthermore, the 
sum of the cytotoxic effects of 5-FU and the p-MWCNTs 
separately were less than the effect of the 5-FU-MWCNTs 
(4%+14% <21% for HeLa, 9%+17% <27% for the 
melanoma cells). These results suggest that, at least in 
vitro, MWCNTs increase the effectiveness of the drug 
while significantly amplifying the cytotoxic effect of 
the two chemotherapies individually applied. Therefore, 
data indicate that the sequential inhibitory effect of the 
5-FU at the “S” phase and the MWCNTs at the “M” 
phase of the cell cycle, as depicted in Figure 1, could be 
complementary. 
A significantly enhanced in vivo effect of 5-FU-
MWCNTs compared to 5-FU 
The anti-tumoral effect of 5-FU-MWCNTs was 
also tested on solid melanoma tumours produced by 
transplantation of B16-F10 cells. This system model is 
Figure 3: Anti-proliferative and cytotoxic effect of 5-FU-MWCNTs in vitro.  Confocal microscopy images of HeLa displaying 
the microtubule network (green channel) and nuclei stained with Hoechst (blue channel). Cells were either untreated (control) or exposed 
to 100 μg/mL p-MWCNTs, 3 μg/mL 5-FU or 100 μg/mL 5-FU-MWCNTs. Treatment with the plain drug triggered a patent increase in the 
cell size and patent anti-proliferative effects in the cultures. Cells treated with identical amounts of 5-FU loaded on MWCNTs displayed 
an enlarged size and apparent magnification of 5-FU anti-proliferative effects. As typical for MWCNTs, some cells also presented long 
cellular extensions resulting of bundled microtubules (solid arrows). Cells dying by apoptosis are also observed (empty arrows). 
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highly representative of most malignant tumours, being 
characterized by local acidosis, edema and abundant 
tumor-associated supporting stromal cells that include 
macrophages [32]. As in previous studies, solid pigmented 
melanoma tumours were treated only once to improve 
reproducibility, with either 5-FU-MWCNTs (2 μg) or 
the controls, namely: (i) the control resuspension media 
(Figure 5, supernatant), (ii) resuspended p-MWCNTs 
(2 μg), or (iii) the free drug (identical amount as 
those supported on the 2 μg of MWCNTs). For direct 
comparison, injections were performed in littermates, in 
a total population of more than 200 mice. All mice were 
sacrificed 4 days post-treatment for analysis. 
Results shown in Figure 5 demonstrate how 4 
days after a single treatment with 5-FU-MWCNTs there 
was an important reduction of the tumor mass. Tumors 
treated intratumorally with the plain drug or p-MWNCTs 
were reduced compared to controls but were significantly 
larger than those treated with de 5-FU physisorbed 
onto MWCNTs. Compared to the control treatment, 
tumoral masses were almost half the size when treated 
with 5-FU-MWCNTs. This effect was significantly 
improved respect to that triggered by the plain drug or 
plain p-MWCNTs. The later also demonstrated a patent 
tumoral growth inhibitory effect confirming previously 
reported data [17]. Summarizing, these experiments 
served to conclude that the important antitumoral 
effect observed for the 5-FU loaded onto MWCNTs 
-reducing in ca. 60% the tumoral mass- results of the 
complementary cytotoxic mechanisms generated by the 
two therapies, interfering with two different steps of the 




High-purity (>98%) MWCNTs were obtained from 
Sigma Aldrich (Ref. 698849). The as-produced MWCNTs 
were washed with HCl to remove impurities, resuspended 
in distilled water by sonication and incubated with a 
solution of ca. 10 mg/mL 5-FU (Accord, Ref. 603544.3). 
The mixture was stirred in a vertical wheel at ca. 20 
r.p.m. for 2 h at room temperature, centrifuged at 12000 
g and washed with distilled water three times in repeated 
cycles of centrifugation (12000 g, 5 min)/redispersion 
(Supplementary  Figure 1). 
The concentration of the physisorbed 5-FU was 
estimated using fluorescence spectroscopy as described in 
the Supplementary Material (Supplementary Figures 1–2). 
TGA was carried out in a TG-DSC Setaram Model Setsys 
Evolution 1750 in air atmosphere. Data were processed 
with the Quadstartm 422 software (T ramp 10.00° C/min to 
830.00° C). 5-FU-Release assays were performed in PBS 
(pH = 7.4) at 37° C. Released 5-FU was measured using 
fluorescence spectroscopy in an Edinburgh Inst. FLSP-920 
using the calibration line of Supplementary Figure 2. 
Cell culture and confocal microscopy imaging
HeLa cells were grown in cultured with Eagle’s 
Minimum Essential Medium (Biowhittaker™). Cells 
were fixed with 4% paraformaldehyde for imaging. 
DNA was stained with Hoechst dye (from Sigma-
Aldrich®). Microtubules were immunostained with 
B512 anti- α-tubulin antibody (Sigma-Aldrich®) and a 
Figure 4: Quantification of the cytotoxic effect of 5-FU-MWCNTs compared to controls. Cultures of HeLa and malignant 
melanoma cells were exposed to p-MWCNTs, soluble 5-FU or 5-FU-MWCNTs during 72 h and were compared to untreated controls. Flow 
cytometry quantitative analysis demonstrates that the cytotoxic effect of the 5-FU when administered as 5-FU-MWCNT is significantly 
enhanced in both, human and murine cancer cells (represented in red). Cell cycle changes evidence a patent blockage in the “S” phase for 
both, 5-FU and 5-FU-MWCNTs treatments (indicated with white lettering).
Oncotarget2027www.oncotarget.com
secondary goat anti-mouse Alexa Fluor 488-conjugated 
IgG (Molecular probes®). Confocal laser scanning and 
phase contrast images were obtained with a Nikon A1R 
confocal microscope. Image processing was performed 
with the NIS-Elements Advanced Research software. All 
fluorescent images are pseudo-colored. 
Tumor studies in vivo
Tumorigenesis was induced by subcutaneous 
transplantation of a total of 2 × 105 B16-F10 murine 
melanoma cells in 10 µL of culture medium containing 
antibiotics following previously described protocols 
[18, 19, 32]. Animal experimentation procedures were 
performed according to EU legislation in accordance with 
the Guidelines for ‘Care and Use of Laboratory Animals’ 
of The University of Cantabria and were approved by the 
local Animal Ethics Committee. Solid pigmented tumours 
were single treated 7 days post-transplant with a unique 
intratumoral dose of 2 µg of nanotubes resuspended 
in a volume of 10 µL of culture medium. Parallel 
experiments comparing the effect of 5-FU-MWCNTs, 
pristine MWCNTs (p-MWCNTs), 5-FU (using equivalent 
calculated amounts) or resuspension media -as an excipient 
control- were performed. To reduce natural artefacts, litters 
were divided in two halves and were injected in parallel 
with two of the former compositions. Tumours masses 
were carefully dissected and weighed 4 days post injection 
for quantitative statistical analyses. Total number of 
animals are indicated in the text and figure.
Flow cytometry and electron microscopy imaging 
Flow cytometry studies were carried out on a 
suspension of fixed cells stained with Hoechst using a 
Becton Dickinson FACS CantoII equipment. This dye 
produces a quantitative staining of DNA that allows 
the determination of changes in the cell cycle and cell 
proliferation blockage, permitting DNA fractional 
quantification (“sub-G1/G0” peak) indicative of apoptosis. 
Three different replicas of the experimental analysis were 
performed on an average of 10,000 cells per condition 
using the FACS Diva software (Becton Dickinson). 
For illustrative purposes the original flow cytometry 
graphs have been substituted by pie charts displaying the 
calculated proportions of the different cell populations, 
including apoptotic cells in Figure 4. Transmission 
Electron Microscopy (TEM) was performed in a JEOL 
JEM 2100 operated at 120 kV on ethanol-dispersed 
samples adsorbed onto a Lacey copper grid. 
Statistical analyses 
A Student’s two-tailed t-test was used for statistical 
analysis and to evaluate significance that was stablished 
for a (*) p = 0.05 or a (**) p = 0.01. The confidence levels 
and total number of events included in the study (n) 
are indicated in the figure legends. Quantitative results 
are expressed as mean values with their corresponding 
standard error bars. 
CONCLUSIONS
The emergence of drug resistance depends 
on the genetic instability, heterogeneity and high 
mutational rate of tumour cells among others. Malignant 
cancer cells continuously develop new mechanisms 
of resistance to chemotherapy that include drug 
destruction, selection of mutations that inhibit drug 
Figure 5: In vivo 5-FU-MWCNTs effects in solid melanoma tumours. (A) Statistical evaluation of the average tumoral weight 
96 h post-treatment (single injection containing 2 μg of p-MWCNTs, 5-FU-MWCNTs or identical amounts of the 5-FU drug). 5-FU-
MWCNTs trigger a statistically significant anti-tumoral effect respect to 5-FU injected locally (t  = 3.6, n = 75, **= t.99) or tumours treated 
with plain p-MWCNTs (t = 1.31, n = 87, *= t.975). (B) Representative mouse littermates bearing solid melanoma tumours 96 h after a single 
intra-tumoral injection of a control resuspension medium or 5-FU-MWCNTs. Arrows point at the tumour location. 
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binding to targets, drug efflux out of the cells, etc. The 
administration of chemotherapy loaded onto MWCNT 
used as nanocarriers can significantly improve many 
different aspects of the traditional chemotherapy. On one 
hand, the penetrating properties of these nanomaterials 
are interesting when considering, for instances, 
treatments applied topically, where CNTs can penetrate 
and spread into the affected lesion transporting the drug 
away from the application point. But more interestingly, 
MWCNTs have intrinsic antitumoral properties that 
can be exploited in cancer treatment interfering with 
microtubule dynamics, triggering effects similar 
to traditional drugs such as Taxol® (paclitaxel) or 
Epothylones. Indeed, the fact that MWCNTs can 
produce notable antitumoral effects in solid tumours 
generated by Taxol®-resistant cells suggests these 
nanofilaments can complement and significantly boost 
chemotherapy. Here we demonstrate how drug and 
nanomaterial therapies can complement each other, 
in vitro and in vivo in the treatment of cancer. 
In conclusion, these data invite to improve anti-
cancer delivery systems considering the use of 
nanomaterials with intrinsic antitumoral properties as 
active excipients, to enhance the therapeutic effect of 
traditional chemotherapy, preventing drug resistance in 
cancer.
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